AzTrials
AzTrials

ObesityDIPPAONCT04887077

Digital Intervention Promoting Physical Activity Among Obese People (DIPPAO)

A study testing Kiplin and face-to-face in people with Obesity and Diabete Type 2, run by University Hospital, Clermont-Ferrand at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Overweight and obesity are today considered among the most important health risks facing humanity with more than one in two adults overweight or obese in western countries. In addition, Type 2 diabetes mellitus (T2DM) is a common comorbidity associated with overweight and obesity and counts for 5% of the French… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Obesity, Diabete Type 2
What is being tested?
Kiplin and face-to-face
Could I receive a placebo?
No, everyone receives an active treatment
How many people
56 participants
Where
1 siteFrance
Study dates
10 Jun 2021to 15 Oct 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject affected for obesity (BMI ≥30 kg/m² and <45 kg/m²) and/or T2DM.
  • Subject treated at the University Hospital of Clermont-Ferrand.
  • The participants must have an iOS (at least iOS8 version) or Android (at least version 5) smartphone.
  • Subjects must also be able to provide informed consent to participate in the research and be covered by health social security.
  • Subjects must be native to any physical activity intervention.
  • Sufficient proficiency of French will be required to ensure the understanding of the questionnaires.

Who cannot join

  • Medical or surgical history judged by the investigator to be incompatible with the study.
  • Subject with an unstable psychiatric condition.
  • Pregnant or breastfeeding women.
  • Heavy alcohol consumption (> 2 to 3 drinks per day depending on gender) or drug addiction.
  • Disability or contraindication to PA.
  • Subject with cardiorespiratory and/or osteoarticular disorders that limit their ability to perform physical tests or moderate PA for 30 minutes.
Show all 14Show fewer
  • Subject with progressive cardiovascular or neoplastic disease.
  • Subject who has presented a major infection in the 3 months prior to inclusion.
  • Subject with a known neuro-muscular pathology (i.e., myopathy, myasthenia, rhabdomyolysis, paraplegia, hemiplegia).
  • Subject with chronic or acute inflammatory pathology within 3 months prior to inclusion.
  • Subject diagnosed and/or treated for schizophrenia, bipolar disorder, major depression.
  • Subject deprived of their liberty by judicial or administrative decision.
  • Subject refusing to sign the written consent to participate.
  • Subject participating in another study.

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000

Other trials in France

About this study

Official title: Digital Intervention Promoting Physical Activity Among Obese People Randomized Controlled Trial: Assessing the Effects of a Digital Intervention to Promote Physical Activity in Patients With Obesity and/or Type 2 Diabetes Mellitus

Overweight and obesity are today considered among the most important health risks facing humanity with more than one in two adults overweight or obese in western countries. In addition, Type 2 diabetes mellitus (T2DM) is a common comorbidity associated with overweight and obesity and counts for 5% of the French population under 65 years of age and 15% in people over 65 years old. Despite the accumulation of scientific evidence supporting the benefits of physical activity, obese and diabetic people remain insufficiently active and current programs struggle to engage and sustain physical activity of patients over long periods of time. It is therefore urgent to develop interventions that can effectively change individuals' behavior. In this context, "e-health" interventions and gamification appear to be a particularly promising avenue to improve physical activity and reduce attrition rates of current programs.

This clinical trial aim to test the effectiveness of a digital intervention based on gamification and teamwork in comparison to a supervised physical activity program. The investigators hypothesized that the intervention will be efficient by the development of a self-determined motivation through the process of gamification on the one hand. On the other hand, through the in-group collaboration with other people who share the same stigmatized criteria that will help participants to overcome weight stigmas, acting generally as physical activity barriers.

Read the detailed description

This trial is a randomized, two-arm intervention design that will examine the efficacy of a digital group-based intervention based on gamification and teamwork among obese and T2DM patients. The experimental arm will be compared to an active control group representing the traditional care program (supervised physical activity).

The digital intervention is composed of four components within a smartphone application: a) a gamification of PA, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool. Accelerometer data, self-reported PA, body composition, and physical capacities will be assessed before, at the end of the intervention and then at the issue of a 6-month follow up. To advance our understanding of complex interventions like gamified and group-based ones, this study will explore several psychological mediators relative to motivation, enjoyment, in-group identification, or perceived weight stigma. Finally, to assess a potential superior efficiency compared to the current treatment (face-to-face supervised PA), this study will include a cost-utility analysis between the two conditions.

Being tested
Kiplin, face-to-face
Keywords
eHealth, Physical activity, Gamification, Mobile app, Behavior change, Cost-utility, Weight stigma
Medical subject headings
Obesity, Diabetes Mellitus, Type 2, Motor Activity, Weight Prejudice

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KiplinDevice

    The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called "animations", b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool.

  • face-to-faceBehavioural

    three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.

Study groups in NCT04887077
Study groupRoleWhat they receive
Kiplin interventionExperimentalKiplin intervention composed of the access to a mobile app and to telecoaching sessions. The number of teleocaching sessions per week will decrease over 3 months.
Receives: Device: Kiplin
face-to-face supervised PA (usual care at the University Hospital of Clermont-Ferrand, France)Active comparatorthree-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
Receives: Behavioral: face-to-face

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in daily physical activity from baseline to 3 months

    The primary outcome will be the change of daily physical activity measured as the daily step count assessed via the Garmin Vivofit 3 (Garmin International Inc., Olathe, KS, USA)

    Measured: Month 3

Secondary outcomes (21)
  1. Change in body composition (BMI) from baseline to 9 months

    in kg/m2

    Measured: Month 9

  2. Change in body composition from baseline to 9 months

    evaluated by bioelectrical impedance analysis

    Measured: Month 9

  3. Change in daily physical activity from baseline to 9 months

    measured as the daily step count assessed via the Garmin Vivofit 3 (Garmin International Inc., Olathe, KS, USA)

    Measured: Month 9

  4. Change in physical activity level from baseline to 9 months

    total physical activity (minutes/day) measured using the Garmin Vivofit 3 (Garmin International Inc., Olathe, KS, USA)

    Measured: Month 9

  5. Change in moderate-to-vigorous physical activity (MVPA) from baseline to 9 months

    measured using a tri-axial accelerometer (ActiGraph GT3x; ActiGraph LLC, Pensacola, FL, USA).

    Measured: Month 9

  6. Change in light physical activity (LPA) from baseline to 9 months

    measured using a tri-axial accelerometer (ActiGraph GT3x; ActiGraph LLC, Pensacola, FL, USA).

    Measured: Month 9

  7. Change in sedentary time from baseline to 9 months

    measured using a tri-axial accelerometer (ActiGraph GT3x; ActiGraph LLC, Pensacola, FL, USA).

    Measured: Month 9

  8. Change in self-reported physical activity from baseline to 9 months

    measured using the RPAQ

    Measured: Month 9

  9. Change in six minute walking distance from baseline to 9 months

    measured via the 6-minute walking test

    Measured: Month 9

  10. Change in muscular strength of the upper limbs from baseline to 9 months

    measured via handgrip measurements

    Measured: Month 9

  11. Change in muscular strength of the lower limbs from baseline to 9 months

    measured via isokinetic dynamometer

    Measured: Month 9

  12. Programme adherence

    number of APA sessions attended. Application engagement and utilization for the experimental group only

    Measured: Month 3

  13. Change in quality of life from baseline to 9 months

    measured via the EQ-5D

    Measured: Month 9

  14. Cost-utility analysis

    measured using incremental cost-effectiveness ratio between the average difference in cost and the average difference in effectiveness (QALY) observed between the two arms

    Measured: Month 9

  15. Perceived enjoyment of physical activity at the end of the intervention

    measured using the Physical Activity Enjoyment Scale (PACES)

    Measured: Month 3

  16. Social identification at the end of the intervention

    measured via the In-group identification questionnaire

    Measured: Month 3

  17. Psychological needs satisfaction at the end of the intervention

    measured via the Psychological Need Satisfaction in Exercise Scale (PNSES)

    Measured: Month 3

  18. Change in motivation toward physical activity from baseline to 9 months

    Autonomous and controlled motivation toward physical activity via the EMAPS.

    Measured: Month 9

  19. Change in weight stigma concerns from baseline to 9 months

    measured using the scale developed by Hunger and Major

    Measured: Month 9

  20. Change in perceived daily discrimination from baseline to 9 months

    measured via the everyday discrimination scale

    Measured: Month 9

  21. Change in weight bias internalisation from baseline to 9 months

    measured via the Modified Weight Bias Internalization Scale (WBIS-M)

    Measured: Month 9

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2021
  2. Study start10 Jun 2021
  3. Primary completion15 Oct 2023
  4. Study completion15 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, randomized, controlled with two parallel arms.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04887077
Sponsor's protocol ID
RBHP 2020 DUCLOS 2
Other IDs
2020-A03091-38
Acronym
DIPPAO
Status last verified
Jul 2026
First submitted
3 May 2021
Last updated
3 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will share de-identified data associated with the collected samples by depositing these data at the Open Science Framework (OSF) repository. The storage will be in Germany (Frankfurt). Data will include demographic, anthropometric, and physical measurements along with data from questionnaires and intervention adherence. We agree that we will identify where the data will be available and how to access the data in any publications and presentations that we author about these data.

Publications

  • Mazeas A, Chalabaev A, Blond M, Mourgues C, Pereira B, Duclos M. Effect of a Digital Health Physical Activity Program Integrating Gamification for Obesity Management in Comparison With Usual Care: Randomized Controlled Trial With an Ideographic Approach. J Med Internet Res. 2025 Nov 28;27:e78376. doi: 10.2196/78376.

    PubMed 41328457
  • Mazeas A, Chalabaev A, Blond M, Pereira B, Duclos M. Digital intervention promoting physical activity among obese people (DIPPAO) randomised controlled trial: study protocol. BMJ Open. 2022 Jun 16;12(6):e058015. doi: 10.1136/bmjopen-2021-058015.

    PubMed 35710254

Questions about this trial

What is this clinical trial studying?

A study testing Kiplin and face-to-face in people with Obesity and Diabete Type 2, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in daily physical activity from baseline to 3 months (time frame: Month 3). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04887077, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in